Antibody-dependent enhancement and vaccine development

References

• Hawkes RA. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci.42, 465–482 (1964).
   PubMedGoogle Scholar
• Halstead SB. Immune enhancement of viral infection. Prog. Allergy31, 301–364 (1982).
   PubMedGoogle Scholar
• Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of Dengue virus growth in human monocytes as a risk factor for Dengue hemorrhagic fever. Am. J. Trop. Med. Hyg.40, 444–451(1989).
   PubMed Web of Science ®Google Scholar
• Morens DM, Halstead SB. Measurement of antibody-dependent infection enhancement of four Dengue virus serotypes by monoclonal and polyclonal antibodies. J. Gen. Virol.71, 2909–2914 (1990).
   PubMed Web of Science ®Google Scholar
• Yang KD, Yeh W-T, Yang M-Y, Chen R-F, Shaio M-F. Antibody-dependent enhancement of heterotypic Dengue infections involved in suppression of IFNγ production. J. Med. Virol.63, 150–157 (2001).
   PubMed Web of Science ®Google Scholar
• Chen R-F, Liu J-W, Yeh W-T et al. Altered T helper 1 reaction but not increase of virus load in patients with Dengue hemorrhagic fever. FEMS Immunol. Med. Micro.44, 43–50 (2005).
   Google Scholar
• Chen R, Yeh W, Yang M-Y, Yang KD. A model of the real-time correlation of viral titers with immune reactions in antibody-dependent enhancement of Dengue-2 infections. FEMS Immunol. Med. Micro.30, 1–7 (2001).
   PubMed Web of Science ®Google Scholar
• Gould EA, Buckley A. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J. Gen. Virol.70, 1605–1608 (1989).
   PubMed Web of Science ®Google Scholar
• Phillpotts RJ, Stephenson JR, Porterfield JS. Antibody-dependent enhancement of tick-borne encephalitis virus infectivity. J. Gen. Virol.66, 1831–1837 (1985).
   PubMed Web of Science ®Google Scholar
• Fust G. Enhancing antibodies in HIV infection. Parasitology115, S127–S140 (1997).
   Google Scholar
• Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol.64, 1437–1440 (1990).
   Google Scholar
• Mascola JR, Mathieson BJ, Zack PM, Walker MC, Halstead BS, Burke DS. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res. Hum. Retroviruses9, 1175–1184 (1993).
   PubMedGoogle Scholar
• Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol.89, 449–463 (1969).
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol.89(4), 435–448 (1969).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89, 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C–CX3CR1 interaction and expression of substance P. J. Virol.77, 9831–9844 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol.73, 8485–8495 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol.72, 2871–2880 (1998).
   PubMed Web of Science ®Google Scholar
• Lidbury BA, Mahalingam S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J. Virol.74, 8376–8381 (2000).
   Google Scholar
• Mahalingam S, Lidbury BA. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-κB) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc. Natl Acad. Sci. USA99, 13819–13824 (2002).
   Google Scholar
• Berman J. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis.16, 397–401 (2003).
   PubMed Web of Science ®Google Scholar
• Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol.166, 1141–1147 (2001).
   PubMed Web of Science ®Google Scholar
• Kima PE, Constant SL, Hannum L et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustatin infection in murine cutaneous leishmaniasis. J. Exp. Med.191, 1063–1067 (2000).
   PubMedGoogle Scholar
• Miles SA, Conrad SM, Alves RG, Jeronimo SMB, Mosser DM. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania.J. Exp. Med.201, 747–754 (2005).
   PubMed Web of Science ®Google Scholar
• Melby PC. Recent developments in leishmaniasis. Curr. Opin. Infect. Dis.15, 485–490 (2002).
   PubMed Web of Science ®Google Scholar
• Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol.167, 6967–6974 (2001).
   PubMedGoogle Scholar
• Gantt KR, Goldman TL, McCormick ML et al. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J. Immunol.167, 893–901 (2001).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jahrling PB Exotic emerging viral diseases: progress and challenges. Nat. Med.10, S110–S121 (2004).
   PubMed Web of Science ®Google Scholar
• Jedrzejas MJ. Unveiling molecular mechanisms of pneumococcal surface protein A interactions with antibodies and lactoferrin. Clin. Chim. Acta367, 1–10 (2006).
   Google Scholar
• Kilian M, Reinholdt J, Lomholt H, Poulsen K, Frandsen EV. Biological significance of IgA1 proteases in bacterial coloization and pathogenesis: critical evaluation of experimental evidence. APMIS104, 321–338 (1996).
   PubMed Web of Science ®Google Scholar
• Weiser JN, Bae D, Fasching C, Scamurra RW, Ratner AJ, Janoff EN. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc. Natl Acad. Sci. USA100, 4215–4220 (2003).
   PubMed Web of Science ®Google Scholar